Unlike traditional targeted therapies that leverage dependencies created by genomic alterations in cancer cells, velcrins instead induce cancer cell death by a novel gain-of-function mechanism mediated by PDE3A-SLFN12 complex formation. The gene discussed is PDE3A; the disease is cancer.